ArticleJournal of medicine and life2025
Ki-67 correlations in breast cancer.
Article in Journal of medicine and life, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastases from breast cancer represent a serious complication, associated with reduced survival and impaired quality of life. Increased patient survival and the limited ability of the blood-brain barrier to be crossed by systemic therapies have led to a rising incidence of these lesions. The molecular profile of metastases may differ from that of the primary tumor in approximately 29% of cases, significantly influencing the choice of targeted treatment. In this retrospective study, we included 100 women who underwent craniotomy for breast cancer brain metastases between 2015 and 2020 at the Prof. Dr. Nicolae Oblu Neurosurgery Clinic, Iași. We recorded demographics (age, residence), latency from primary diagnosis to brain metastasis, and MRI features (number, location, edema, hemorrhage). Histopathology and immunohistochemistry included GATA3, CK5/6, ER, PR, HER2, and Ki-67 using standardized protocols. ER/PR positivity was defined as ≥1% nuclear staining; HER2 was scored 0-3+ per ASCO/CAP; Ki-67 was reported as a percentage index. The most frequent metastatic subtypes were HER2-positive (32%) and triple-negative (25%). The mean Ki-67 index was 48.2% and showed a significant inverse correlation with the time from primary breast cancer diagnosis to brain metastasis (r = -0.57; P < 0.001). Higher Ki-67 values were associated with hemorrhagic lesions, while lower values occurred in solitary metastases. Patients receiving hormonal therapy had longer median survival (29.5 months) compared to those receiving targeted therapy (11.9 months; P < 0.001). Immunohistochemical profiling of brain metastases from breast cancer, focusing on ER, PR, HER2, and Ki-67, revealed specific correlations between tumor proliferation, time to metastasis, and neuroimaging features such as hemorrhage and lesion location. HER2-positive and triple-negative subtypes showed higher brain metastatic potential and poorer outcomes with targeted therapy, while luminal tumors responded better to hormonal treatment. The inverse correlation between Ki-67 and metastasis latency, as well as its association with aggressive imaging phenotypes, represents an original contribution of this study, underscoring the need for tailored therapeutic strategies based on combined pathological and imaging data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.